This brand name is authorized in Austria, Ecuador, Estonia, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, United Kingdom, United States, South Africa
The drug PHESGO contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Pertuzumab
UNII K16AIQ8CTM - PERTUZUMAB
|
|
Pertuzumab is a recombinant humanised monoclonal antibody that specifically targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). Pertuzumab inhibits ligand-initiated intracellular signalling through two major signal pathways, mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase (PI3K). Inhibition of these signalling pathways can result in cell growth arrest and apoptosis, respectively. |
|
2
Trastuzumab
UNII P188ANX8CK - TRASTUZUMAB
|
|
Trastuzumab is a recombinant humanised IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). Τrastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumour cells that overexpress HER2. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| PHESGO Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01FY01 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FY Combinations of monoclonal antibodies and antibody drug conjugates | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 195-MBE-0521, 196-MBE-0521 |
| Country: EE | Ravimiamet | Identifier(s): 1835995, 1836008 |
| Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 438330, 535672 |
| Country: FR | Base de données publique des médicaments | Identifier(s): 63806777, 67178992 |
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 393038, 393041 |
| Country: HK | Department of Health Drug Office | Identifier(s): 67118, 67119 |
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 9030, 9031 |
| Country: IT | Agenzia del Farmaco | Identifier(s): 049288018, 049288020 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1091695, 1091696 |
| Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 207306, 207322 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100443830, 100443846 |
| Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W67286001, W67296001 |
| Country: US | FDA, National Drug Code | Identifier(s): 50242-245, 50242-260 |
| Country: ZA | Health Products Regulatory Authority | Identifier(s): 55/30.1/0444, 55/30.1/0445 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
